Standout Papers

Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Act... 1997 2026 2006 2016 505
  1. Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus (1997)
    Syd Johnson, Cynthia N. Oliver et al. The Journal of Infectious Diseases

Immediate Impact

5 by Nobel laureates 25 from Science/Nature 57 standout
Sub-graph 1 of 24

Citing Papers

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
2023 Standout
Respiratory syncytial virus infection and novel interventions
2023 Standout
10 intermediate papers

Works of Eric Tsao being referenced

Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus
1997 Standout

Author Peers

Author Last Decade Papers Cites
Eric Tsao 84 224 276 480 20 851
Nick M. Cirino 113 231 297 436 21 846
Lucy Beales 40 294 166 420 14 933
M. Ohuchi 77 223 181 568 24 941
Ebenezer Tumban 43 370 277 537 30 1.2k
Eloi Kpamegan 31 134 460 552 18 853
C C Patrick 20 339 273 416 34 1.1k
Vincent Pavot 62 326 328 327 32 1.1k
John T. Bates 39 208 310 370 37 1.0k
Joshua M. DiNapoli 53 150 407 732 22 960
G. Leadbetter 38 182 355 770 9 946

All Works

Loading papers...

Rankless by CCL
2026